The dwindling stock of antibiotics, and what to do about it
Pharmaceutical companies have largely abandoned the business of discovering and developing antibiotics and our stock of these “miracle drugs” is beginning to shrink. Michael Kinch and his colleagues at Washington University in St. Louis are working to create new models for drug discovery that could replace the failed private enterprise model.